GLP-1 side effects and 'Ozempic face': what TikTok gets wrong

What did @carissaaalynnn actually say?

Honestly, this is less a health claim and more an unboxing gone sideways. The creator received what appears to be a GLP-1 medication, expressed confusion about whether she got the right product, and then asked whether "two vials" would last her three months. She also said she expects to be significantly smaller in three months. There is no dosing advice here, no product name given clearly, and no explicit medical claim. That context matters.

What we can work with: she is implying that a two-vial supply is expected to cover a 90-day course of treatment, and that she anticipates meaningful weight loss in that window. Those two assumptions are worth unpacking, because one is plausible depending on the medication and dose, and the other is shaped by expectations that the clinical data sometimes struggles to meet.

Does the science back this up?

The weight loss expectation is in the right ballpark, though it depends heavily on which GLP-1 she is using. The landmark STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found that semaglutide 2.4 mg weekly produced an average 14.9% body weight reduction over 68 weeks, with meaningful change visible by week 12. Tirzepatide data from the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed even stronger results, up to 22.5% at 72 weeks.

Three months is enough time to see real movement on the scale for most people, but "being the size of an amp" is personal and vague. Some people respond quickly. Others plateau early. Genetics, starting dose, adherence, and diet all shift the outcome. Expecting dramatic transformation in 90 days is not wrong, but it is optimistic depending on where someone starts their titration period.

What did they get wrong (or right)?

The vial confusion is understandable but worth addressing. Compounded GLP-1 medications, which many patients receive through telehealth platforms, are typically packaged differently than brand-name injectable pens. A vial-based format requires the patient to draw their own dose using a syringe, which introduces real variability in how long a vial lasts. Two vials lasting three months is possible if the dose is low and the volume per vial is sufficient, but it is not a universal truth.

Compounded semaglutide and brand-name semaglutide are not the same product. The FDA has stated this explicitly. Compounded versions are not FDA-approved, and their concentration, sterility, and inactive ingredients can vary by pharmacy. This does not mean they are unsafe, but a patient doing mental math on vial longevity without understanding their prescribed concentration could easily under-dose or over-dose. That is a real problem, not a theoretical one.

What should you actually know?

If you are using a vial-based GLP-1 medication, the number of doses you get depends on the concentration of the solution (usually expressed as mg/mL), your prescribed dose in milligrams, and the total volume in the vial. None of that is visible in this video, so the "two vials for three months" math cannot be verified without knowing those specifics.

Patients starting GLP-1 therapy typically begin at a low dose and titrate upward over weeks. At a starting dose, two vials might last considerably longer than three months. At a maintenance dose, they might not last that long at all. The American Diabetes Association's Standards of Care (2024) recommend individualized dose escalation, not a fixed timeline. If your vial count does not match your prescription instructions, the right call is to contact your prescribing provider directly, not do the math yourself on TikTok.